Joe Q. Wei
Chris O'Brien Lifehouse, 119-143 Missenden Road
Camperdown, NSW 2050, Australia
Camperdown, NSW 2050, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Measuring What Matters: RECIST Response Does Not Predict HRQoL in Early-Phase Clinical Trials.
Journal: Cancers
Published: February 06, 2026
Assessing Patient-Reported Financial, Social, and Time Toxicity in Early-Phase Cancer Clinical Trials in Australia Through a Prospective Multicenter Nonrandomized Cohort Study.
Journal: JCO oncology practice
Published: November 03, 2025
Clinical outcomes and management of CDKN2A/B homozygously deleted IDH-mutant astrocytomas-a cohort study and patterns of care survey.
Journal: Neuro-oncology practice
Published: October 13, 2025
Vaccine-induced immunity is maintained in glioma patients relative to other solid tumours.
Journal: Journal of neuro-oncology
Published: September 02, 2025
Prospective assessment of health-related quality of life in early phase oncology clinical trials: PEARLER.
Journal: JNCI cancer spectrum
Published: June 17, 2025
A protocol for pre-treatment testing for antibodies to galactose-alpha-1,3-galactose to mitigate the risk of cetuximab hypersensitivity reactions - a retrospective cohort review.
Journal: Cancer treatment and research communications
Published: April 10, 2025
Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study.
Journal: JNCI cancer spectrum
Published: December 23, 2024
The APPLE's core question-upfront osimertinib versus the sequential approach for EGFR mutated non-small cell lung cancer.
Journal: Journal of thoracic disease
Published: December 20, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 18, 2024
Therapeutic drug monitoring of osimertinib in EGFR mutant non-small cell lung cancer by dried blood spot and plasma collection: A pilot study.
Journal: British journal of clinical pharmacology
Published: October 30, 2023
First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study.
Journal: Frontiers in oncology
Published: October 02, 2023
Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer.
Journal: Journal of geriatric oncology
Published: July 31, 2023
Last Updated: 09/26/2026